Last updated: July 20, 2026
Gilead v. Teva (1:18-cv-00466): litigation summary, claims at issue, and exclusivity impact
Executive summary: In Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-00466, Gilead sued Teva in federal court over ANDA-linked patent infringement tied to Gilead’s marketed antiviral product (claims tied to the Orange Book patent set for the referenced NDA). The case posture is typical of Hatch-Waxman practice: Gilead asserts infringement of one or more Orange Book-listed patents; Teva counters with noninfringement, invalidity, and FDA submission defenses, with the court determining whether Teva’s ANDA would infringe and whether the asserted patents are enforceable. The litigation outcome determines Teva’s timing risk for generic entry and informs Gilead’s remaining patent and exclusivity runway.
Because the case caption you provided contains only the docket number and no case documents (complaint, amended pleadings, claim chart, Markman order, or settlement/judgment), a complete, accurate litigation summary cannot be produced from the provided information alone.
What patents protect Gilead’s product in Gilead v. Teva (1:18-cv-00466)?
A complete, accurate answer requires the exact Orange Book listed patents asserted in the complaint, including:
- patent numbers asserted,
- claim numbers asserted (independent and dependent),
- Orange Book NDA reference for the marketed product,
- active ingredient and dosage form at issue,
- and any later narrowing via amended pleadings.
Without those complaint-level particulars, listing specific patents and claim coverage would risk omission or misidentification.
How do you identify the asserted patent set in this docket?
The asserted set is normally traceable from:
- the complaint’s infringement counts, and
- the pretrial order / final judgment naming the patents and claims the court addressed.
What is the litigation timeline for 1:18-cv-00466?
A full timeline requires docket events such as:
- complaint filing date,
- Teva’s answer and defenses,
- any amended complaint,
- claim construction (Markman) schedule and order,
- dispositive motions (summary judgment, Daubert if relevant),
- trial dates or the procedural endpoint (dismissal, settlement, or final judgment),
- and any post-judgment motions and appellate activity.
Without docket events or orders, any dates would be speculative.
Which court orders mattered in Gilead v. Teva (1:18-cv-00466)?
A credible litigation analysis depends on specific legal determinations, usually including:
- claim construction for the asserted claims,
- standards used for infringement and invalidity,
- whether the court addressed:
- anticipation or obviousness under 35 U.S.C. §§ 102/103,
- indefiniteness under 35 U.S.C. § 112(b),
- written description and enablement under § 112(a),
- and prosecution history estoppel or claim scope limits.
Those determinations are not available from the docket number alone.
How strong were Gilead’s asserted patents in this case?
Patent strength analysis requires:
- which patents were asserted,
- the court’s claim construction outcomes (especially for limiting terms),
- the invalidity theories raised,
- and the court’s reasoning in any final order (or settlement posture if the case ended pre-merits).
Without the court’s substantive rulings or the asserted claim set, strength cannot be quantified.
Did Teva challenge validity via Paragraph IV arguments in 1:18-cv-00466?
ANDA patent challenges typically reflect Paragraph IV certifications under 21 U.S.C. § 355(j)(2)(A)(vii)(IV). A proper analysis requires the record showing:
- which patents Teva certified against,
- whether Teva’s theory was invalidity, noninfringement, or both,
- and whether any court findings resolved those positions.
What is the Orange Book status of the patents at issue?
This requires the Orange Book listing for the relevant reference product and strength categorization (patent listed, expiration dates, pediatric exclusivity extensions, and listing status). That data cannot be correctly mapped to the docket without the referenced NDA/product.
When does the relevant patent estate lose exclusivity?
To answer precisely, you need:
- the latest expiration date among the asserted patents,
- any terminal disclaimers or ownership/assignment history that affect expiration,
- and exclusivity extensions (including pediatric exclusivity if applicable).
What generic entry risks exist for Teva following 1:18-cv-00466?
Generic entry timing risk depends on:
- whether the asserted patents were held invalid or not infringed,
- whether the case settled with an agreed “carve-out” entry date,
- whether any remaining unasserted patents still block approval,
- and whether FDA approval is timed to patent expiry or settlement.
None of those determinations are available from the docket number alone.
What settlement or judgment affected launch timing in this case?
To summarize and analyze settlement:
- settlement date,
- scope (which strengths/forms/therapeutic indications were covered),
- agreed entry date,
- compensation or royalty terms if any,
- and any covenants not to sue.
To summarize and analyze a judgment:
- the asserted patents found infringed or invalid,
- remedies (injunction scope, damages if awarded),
- and whether there was an appellate path.
No settlement/judgment information is provided.
How does this case compare with other Gilead vs. Teva Hatch-Waxman litigations?
A comparison requires:
- identification of Gilead products repeatedly litigated against Teva,
- docket outcomes for those other cases,
- and the patent patterns (formulation vs method-of-use vs composition of matter).
Without the product and patent set in 1:18-cv-00466, a comparison would be unreliable.
Key Takeaways
- A litigation summary tied to patent numbers, claim constructions, court holdings, and launch implications cannot be produced from docket number alone.
- High-stakes decisioning in Hatch-Waxman cases requires the complaint’s asserted patent list and the court’s dispositive orders or settlement terms.
FAQs
- What information is required to map 1:18-cv-00466 to the Orange Book patents asserted?
- How do Markman claim constructions typically change infringement outcomes in ANDA patent cases?
- What outcomes (invalidity vs noninfringement vs settlement) most affect FDA approval timing?
- How are method-of-use and formulation patents treated differently from composition-of-matter in infringement analyses?
- What filings indicate whether Teva’s ANDA was carved out in a settlement agreement?
References
- None provided in the prompt.
